58 results about "Medication abuse" patented technology

An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.

A method and compositions for treating a patient that prevent or reduce drug abuse and overdose events.

A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and / or pharmaceutically acceptable salt thereof and a sub-therapeutic amount of opioid antagonist and / or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.

The invention relates to mobile phone software for behavior intervention aiming at MSM. The mobile phone software for MSM behavior intervention comprises modules of health assessment, health education, behavior change planning, forum and the like. Behavior assessment aiming at MSM can be performed, a pertinent behavior change plan and a personal incentive plan can be formulated, thus daily behavior feedback and weekly behavior assessment can be performed, education of knowledge about AIDS can be performed, sexual behaviors, drug abuse, medication compliance for antiviral therapy of HIV positive patients and the like can be intervened, and thus the purposes of preventing AIDS virus infection and promoting physical and psychological health can be achieved.

A device for deterring drug abuse includes a housing configured to contain a drug accessible through an access port. The device includes a physical deterrent configured to move from an unsecured position, wherein the access port of the housing is normally accessible, to a secure position, wherein the access port of the housing is normally inaccessible. The device further includes a locking mechanism that is coupled with the physical deterrent. The locking mechanism has a locked mode, wherein the physical deterrent does not normally move from the secure position to the unsecured position. The locking mechanism is further coupled with a deterrent container having a deterrent substance. The device is configured such that attempts to access the drug when the physical deterrent is in the secure position, and when the locking mechanism is in the locked mode, activate the release of the deterrent substance to the drug.

A method and compositions for treating a patient that prevent or reduce drug abuse and overdose events.

The invention provides methods for diagnosing, assessing or quantitating drug use, drug abuse or narcosis or for differentiating drug use, drug abuse or narcosis from brain injury in a subject by tracking eye movement of at least one eye of the subject, analyzing eye movement of at least one eye of the subject, comparing eye movement of at least one eye of the subject the normal or mean eye movement; and, optionally calculating a standard deviation or p value for eye movement of at least one eye of the subject as compared to the normal or mean eye movement.

The invention provides a pharmaceutical composition for treating diabetes and a preparation method thereof, and relates to the technical field of medicines. The pharmaceutical composition for treating the diabetes comprises cereal dietary fibers, whey protein, milk powder, acerola cherries, Chinese wolfberry fruits, silybum marianum, a white kidney bean extract, chia seeds, psyllium seed husks, cordyceps militaris, cordyceps sinensis, oyster peptides, anoectochilus formosanus, lecithin, dendrobium officinale, selenium-enriched yeast powder, natto powder, vitamins, a sweetening agent, prebiotics and a calcium agent. Through mutual matching of specific components, the pharmaceutical composition can effectively control blood sugar and restore immunity. Moreover, all the components are medicinal and edible raw materials, so that the effects of purifying blood and reducing blood sugar can be achieved for patients through dietetic invigoration, and the pharmaceutical composition is green, safe and free of toxic and side effects, so that injury caused by abuse of medicines is effectively avoided.

A method to treat carfentanyl overdose comprising administrating a pharmaceutical formulation in the form of liquid solution for spray administration by the nasal and / or buccal route containing naltrexone as active ingredient in amounts greater than 1%.

The invention relates to new morphine derivatives deuterated at the 7,8-position of the morphine ring, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them. The new deuterated morphine derivatives show high and selective μ-opioid receptor binding activity leading to the benefit of higher analgesic activity at lower dosages inducing thereby reduced adverse effects compared to the hydrogenated derivatives. The compounds of the invention are useful for example in the treatment of pain or can be used as antitussive agents with a reduced risk of the possibility of drug abuse.

An automated system and method for determining drug testing. The system enters a participant or subject into the system who is to be monitored during a probationary or other program for alcohol or drug abuse offenders. The system provides a watch for the participant to wear and record sleep pattern information of the participants through their movements and intensity of those movements. The system uploads the sleep pattern information into the computer system and conducts various tests to analyze the sleep pattern information for determining if the participant or subject has been using alcohol or other drugs and should be subjected to a confirming urinalysis exam.

The present invention relates to combinations and methods for the treatment of neurological disorders related to amyloid beta toxicity and / or neuronal death and / or glucose-impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease-related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and / or neuronal death. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, Parkinson's disease, Lewy body dementia, multiple system atrophy and other related synucleinopathies, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on 3-phenylsulfonyl-8-(piperazin-1-yl) quinoline and baclofen and / or acamprosate.